

## First patient enrolled in Oncopeptides' glioblastoma study

STOCKHOLM – June 17, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the first patient has been enrolled in the clinical "Window-of-Opportunity" (WoO) study evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.

"Enrolling the first patient in our glioblastoma study is an important step that shifts our brain cancer program from pre-clinical and a regulatory milestone to active clinical assessment" says **Sofia Heigis, CEO of Oncopeptides**. "Following our swift regulatory approval, this trial allows us to efficiently generate human clinical data in a highly underserved indication, potentially demonstrating the true versatility of our PDC platform as we look to expand our pipeline beyond multiple myeloma."

The WoO study, named OP-701 (INSULA), represents the first clinical evaluation of a PDC in glioblastoma, marking a major strategic milestone as Oncopeptides expands its core technology platform beyond multiple myeloma. The focused trial will enroll approximately 10 patients to provide initial human proof-of-concept to assess that the company's technology successfully penetrates the human blood-brain barrier (BBB) in glioblastoma patients and have cytotoxic (cell killing) activity in tumor cells.

The BBB remains the primary clinical obstacle and causes most traditional oncological drugs to fail in this disease.

By utilizing an approved drug from Oncopeptides' platform as a "clinical probe," the study employs an innovative and highly efficient design to capture drug activity directly within the tumor tissue from patients scheduled for surgery for recurrent disease. This approach aims to validate the underlying biological mechanism in a rapid, cost-efficient manner before advancing a PDC asset into formal dose-finding and potential further clinical trials.

Glioblastoma is the most aggressive and devastating form of brain cancer, characterized by rapid tumor growth, invariable relapse, and a total lack of curative options, with a median survival rate of just 12–15 months.

The global glioblastoma market represents a profound unmet medical need and is estimated to be worth more than 8 billion USD by 2035. Oncopeptides' PDC molecules are believed to be uniquely equipped to pass the blood-brain barrier due to their small size and lipophilicity, entering the target cancer cells freely to deliver their cytotoxic payload directly where it is needed.

The trial is conducted at Oslo University Hospital in Norway.

For more information, including questions and answers for investors, please visit [www.oncopeptides.com](http://www.oncopeptides.com).

**For more information, please contact:**

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: [ir@oncopeptides.com](mailto:ir@oncopeptides.com)

Cell phone: +46 76 229 38 68

**About Oncopeptides**

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 70 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: [www.oncopeptides.com](http://www.oncopeptides.com)

**Attachments**

[First patient enrolled in Oncopeptides' glioblastoma study](#)